People living with HIV are more likely to develop lung cancer compared with the general population, which may be related to a higher rate of smoking and immune suppression, according to study results published in The Lancet HIV. The good news is that lung cancer among HIV-positive people has declined over time, especially for younger age groups.
“The reduction in risk for lung cancer in people living with HIV is most pronounced among those younger than 50 years, who show substantial decreases in relative excess risk compared with the general population,” the study authors wrote. “However, for the increasing proportion of people living with HIV who are living beyond the age of 50 years, the absolute risk of lung cancer has surpassed that of common AIDS-defining cancers and is a considerable excess risk and public health burden.”
Prior research has shown that people with HIV are more likely to develop several types of cancer, including both AIDS-related cancers, such Kaposi sarcoma and non-Hodgkin lymphoma, and malignancies that are not directly attributed to HIV. Lung cancer is estimated to be the second most common cancer among people living with HIV in the United States, and it could account for 15% of all cancers in this population by 2030, the authors noted as background. But there has been little recent research on the risk of lung cancer in this group.
Cameron Haas, PhD, and Meredith Shiels, PhD, of the National Cancer Institute, and colleagues looked at lung cancer rates among people living with HIV using 2001 to 2016 data from the HIV/AIDS Cancer Match study, which links data from HIV and cancer registries from 11 states, Puerto Rico and Washington, DC.
The analysis included HIV-positive people ages 20 to 89 years. Three quarters were men, about half were Black, roughly a quarter were white and a quarter were Latino. The HIV population aged during the study period, with the proportion of people ages 50 or older doubling during 2001 to 2004 and 2013 to 2016. However, the proportion with a prior AIDS diagnosis, indicating advanced immune suppression, declined from 65% to 55%.
A total of 3,426 cases of lung cancer were identified during more than 4 million person-years of follow-up, for an overall incidence rate of 79.4 cases per 100,000 person-years. Adenocarcinoma (40%) and squamous cell cancer (25%) were the most common types, similar to the distribution in the general population. Black and white people with HIV had comparable lung cancer rates while Latinos had a lower rate. Men and women who inject drugs had a significantly elevated lung cancer risk compared with men who have sex with men.
Lung cancer incidence for people with HIV fell substantially during the study period, from 124.4 cases per 100,00 person-years during 2001 to 2004 to 58.3 per 100,000 person-years during 2013 to 2016. The overall incidence rate declined by 6% per year over the course of the study, with a greater decline among younger people: an 11% drop for those ages 20 to 29 versus a 5% drop for those ages 50 to 59 and a 3% drop for those ages 70 to 89 years. Latinos saw a larger drop (9%) than Black people (6%) or white people (4%).
The standardized incidence (SIR) ratio for lung cancer (a method of comparing rates in different populations) fell from 2.49 during 2001 to 2004, meaning HIV-positive people were two and a half times more likely than HIV-negative people to develop the malignancy, to 1.48 during 2013 to 2016, meaning people with HIV were 48% more likely to develop lung cancer. HIV-positive women who inject drugs had the greatest excess risk relative to their HIV-negative counterparts (SIR 3.27), while gay and bisexual men had the least excess risk (SIR 1.13).
However, there was considerable variation by age, with younger HIV-positive people showing a greater decline relative to HIV-negative people over time. In the 20 to 39 age group, people with HIV were about five times more likely to develop lung cancer during 2001 to 2004, but the risk was no longer significantly elevated during 2013 to 2016. Among those ages 40 to 49, the standardized incidence ratio for people with HIV was 2.01 during 2013 to 2016, or about double the risk of HIV-negative people, down from 3.14 during 2001 to 2004. During 2013 to 2016, HIV-positive people ages 50 to 59 were about 60% more likely and those ages 60 to 69 were about 30% more likely than HIV-negative people to develop lung cancer (SIR 1.61 and 1.31, respectively), but those over 70 were not at significantly higher risk than their HIV-negative peers.
Not surprisingly, since the likelihood of lung cancer increases with age, older people with HIV had the highest absolute risk (1,650 cases per 100,000 people over five years for those ages 70 and older versus 20 cases per 100,000 for those ages 20 to 39). Older people also had the greatest excess absolute risk, or number of extra cases compared with their HIV-negative peers. During 2013 to 2016, HIV-positive people ages 60 to 69 had 48 additional cases per 100,000 person-years. For people over 50, the incidence of lung cancer equaled or exceeded that of non-Hodgkin lymphoma and Kaposi sarcoma starting in 2011.
“Between 2001 and 2016, the risk of lung cancer decreased for people living with HIV aged 20 to 69 years but remained substantially elevated compared with the general population, probably due to a combination of smoking and immunosuppression,” the study authors concluded. “For people living with HIV aged 60 years and older, the risk of lung cancer exceeds that of two of the most common AIDS-defining cancers, highlighting the importance of lung cancer among the growing older population of people living with HIV.”
Although data on smoking status were not available in this study, surveys done during the same period found that the estimated rate of smoking was 47% among people with HIV—nearly twice the 26% rate in the general population. The authors noted that smoking might explain the excess risk of lung cancer among older people, but it wasn’t enough to account for the higher risk in the younger groups.
In 2021, the U.S. Preventive Services Task Force updated its guidelines for the general population to recommend annual lung cancer screening for people ages 50 to 80 who have at least a 20 pack-year smoking history (the equivalent of one pack of cigarettes a day for 20 years). This is up from age 55 and a 30 pack-year smoking history in the previous guidelines. But prior research suggests that people with HIV might benefit from starting screening sooner. In an accompanying commentary, Adam Januszewski, MBBS, PhD, of St. Bartholomew’s Hospital, and Mark Bower, MD, PhD, of Chelsea and Westminster Hospital in London, suggested that HIV status should perhaps be considered for inclusion in lung cancer screening criteria.
In addition to smoking, immunosuppression and pulmonary inflammation likely also play a role in the development of lung cancer, the study authors suggested. A previous study in France found that the excess risk of lung cancer among people with HIV was smaller if they were on effective antiretroviral therapy and experienced CD4 cell recovery. Conversely, a prior AIDS diagnosis was associated with an increased risk of lung cancer in the present study.
“Declines in the risk of lung cancer for people living with HIV probably reflect improvements in access to and treatment with combined antiretroviral therapy, especially for the youngest age group (aged 20 to 39 years),” the researchers wrote. “Prevention and detection of lung cancer for people living with HIV should be prioritized for the growing proportion of individuals older than 50 years.”
Click here to read the study abstract.